Global Kinetics' PKG being trialled in the UK
Global Kinetics Corporation will provide its Parkinson’s KinetiGraph (PKG) devices for a 12-month pilot trial in the UK.
Parkinson's research and support charity Parkinson’s UK will enable access to the devices to up to 200 patients throughout the UK.
The PKG is a wrist-worn technology that automatically records specific movement data that can be used to inform dosing regimens and monitor symptoms.
Patients involved in the pilot program will wear the technology for 10 days prior to specialist consultation to allow information about their symptoms to be tracked.
“This is a new way of managing Parkinson’s and we eagerly await the outcome of this important evaluation program,” Parkinson’s UK CEO Steve Ford said.
“Mobile health technologies provide a new opportunity to monitor and manage this debilitating movement disorder affecting an estimated 127,000 people in the UK alone.”
Global Kinetics CEO Andrew Maxwell said he is confident that PKG will become a routine Parkinson’s management tool throughout the UK.
“We know this technology is highly effective at monitoring the key movement disorder symptoms of Parkinson’s, dyskinesia and bradykinesia,” he said. “When clinicians have this information, they can tailor medication regimes for optimal symptom management and ultimately enable improved quality of life.”
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
